Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retinal pigment epithelial cell replacement therapy - Genentech/Lineage Cell Therapeutics/Roche

Next Previous
Search
Drug Profile

Retinal pigment epithelial cell replacement therapy - Genentech/Lineage Cell Therapeutics/Roche

Alternative Names: OpRegen; OpRegen-Plus; OpRegen® RPE cells; Retinal pigment epithelium transplant therapy; RG-6501; Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells

Latest Information Update: 21 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Cure Neurosciences
  • Developer Cell Cure Neurosciences; Genentech; Lineage Cell Therapeutics
  • Class Cell therapies; Pluripotent stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dry age-related macular degeneration; Dry macular degeneration

Most Recent Events

  • 30 Sep 2024 Retinal pigment epithelial cell replacement therapy - Genentech/Lineage Cell Therapeutics/Roche receives Regenerative Medicine Advanced Therapy (RMAT) status for Dry macular degeneration in USA
  • 09 May 2024 Efficacy data from a phase I/IIa trial in Dry age related macular degeneration released by Lineage Cell Therapeutics
  • 09 May 2024 Roche plans to file regulatory application for Dry macular degeneration in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top